Abstract
Influenza virus vaccine (IVV) is a promising research domain that is closely related to global health matters, which has been acknowledged not only by scientists and technology developers, but also by policy-makers. Meanwhile, patents encompass valuable technological information and reflect the latest technological inventions as well as the innovative capability of a nation. However, little research has examined this up-and-coming research field using patent bibliometric method. Thus, this paper (a) designs the technology classification system and search strategy for the identification of IVV; and (b) presents a longitudinal analysis of the global IVV development based on the European Patent Office (EPO) patents. Bibliometric analysis is used to rank countries, institutions, inventors and technology subfields contributing to IVV technical progress. The results show that the global trends of IVV are a multi-developing feature of variety but an uneven technical resource distribution. Although the synthetic peptide vaccine is a comparatively young field, it already demonstrates the powerful vitality and the enormous development space. With the worldwide competition increasing, all nations especially China should be looking to increase devotion, enhance capability and regard effectiveness of technological innovation.
Highlights
The influenza virus vaccine (IVV) is a vaccination using a vaccine for a given time to protect against the highly variable influenza virus [1]
Influenza virus vaccine (IVV) can be divided into four major categories, including inactivated vaccine (IV), live attenuated vaccine (LAV), recombinant vaccine (RV), and synthetic peptide vaccine (SPV), whereas it can be further divided into eight subcategories: inactivated virus vaccine, split vaccine, subunit vaccine, live attenuated vaccine, recombinant protein vaccine, recombinant vector vaccine, recombinant
According to the International Patent Classification (IPC) groups corresponding to the number of patents, we found that the technical topics of global IVV patent mainly concentrate on the immune test material orthomyxoviral (A61K39/145), anti-infectives for influenza or rhinovirus (A61P31/16), and virus and its composition, preparation, or purification (C12N7/00) and so on
Summary
The influenza virus vaccine (IVV) is a vaccination using a vaccine for a given time to protect against the highly variable influenza virus [1]. Since influenza viruses are continuously changing, vaccination is the best way to protect oneself against the flu. U.S Centers for Disease Control and Prevention (CDC), seasonal flu vaccines had excellent track records of safety for more than 50 years. For this reason, IVV is commonly considered as PLOS ONE | DOI:10.1371/journal.pone.0136953. Patent Bibliometric Analysis of Global Influenza Virus Vaccine a hopeful research domain in the context of pressing global challenges related to health care, fresh air, clean water, and climate change. Many countries and public health organizations have initiated their research and development (R&D) projects in various forms, such as a huge investment in technical platform and infrastructures.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call